Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Farah R W Kools

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Mededpublish (2016)|December 25, 2023
Practical tips for organizing challenge-based learning in biomedical educationFarah R W Kools, Heleen van Ravenswaaij
Anti-Cancer Drugs|August 18, 2017
CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growthPatrick M Reeves, Mojgan A Abbaslou, Farah R W Kools, et al.
Frontiers in Medicine|May 22, 2023
One size does not fit all: an exploratory interview study on how translational researchers navigate the current academic reward systemFarah R W Kools, Christine M Fox, Berent J Prakken, et al.
BMC Medical Education|October 10, 2024
International online mentorship for translational researchersFarah R W Kools, Christine M Fox, Harold V M van Rijen, et al.
BMC Medical Education|December 19, 2024
A mixed method study investigating the key translational competencies acquired during a challenge-based courseFarah R W Kools, Christine M Fox, Berent J Prakken, et al.
Journal of Cellular Physiology|November 3, 2018
Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transitionOlivier G de Jong, Lizet M van der Waals, Farah R W Kools, et al.
Oncotarget|December 8, 2017
Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent micePatrick M Reeves, Mojgan A Abbaslou, Farah R W Kools, et al.
Oncotarget|August 14, 2018
Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent micePatrick M Reeves, Mojgan A Abbaslou, Farah R W Kools, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Mededpublish (2016)|December 25, 2023
Practical tips for organizing challenge-based learning in biomedical educationFarah R W Kools, Heleen van Ravenswaaij
Anti-Cancer Drugs|August 18, 2017
CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growthPatrick M Reeves, Mojgan A Abbaslou, Farah R W Kools, et al.
Frontiers in Medicine|May 22, 2023
One size does not fit all: an exploratory interview study on how translational researchers navigate the current academic reward systemFarah R W Kools, Christine M Fox, Berent J Prakken, et al.
BMC Medical Education|October 10, 2024
International online mentorship for translational researchersFarah R W Kools, Christine M Fox, Harold V M van Rijen, et al.
BMC Medical Education|December 19, 2024
A mixed method study investigating the key translational competencies acquired during a challenge-based courseFarah R W Kools, Christine M Fox, Berent J Prakken, et al.
Journal of Cellular Physiology|November 3, 2018
Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transitionOlivier G de Jong, Lizet M van der Waals, Farah R W Kools, et al.
Oncotarget|December 8, 2017
Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent micePatrick M Reeves, Mojgan A Abbaslou, Farah R W Kools, et al.
Oncotarget|August 14, 2018
Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent micePatrick M Reeves, Mojgan A Abbaslou, Farah R W Kools, et al.
Pageof 1